Drug/cyclodextrin solid systems in the design of hydrophilic matrices: a strategy to modulate drug delivery rate.
The aim of this study was to investigate how the delivery rate of erodible sustained-release hydrophilic matrices intended for the delivery of poorly soluble drugs can be optimized through the incorporation of drug/cyclodextrin binary systems. Carvedilol (CAR), a sparingly water-soluble antihypertensive drug, was selected as a model for the study. As first, we attempted to improve CAR apparent solubility by association with hydroxypropyl-beta-cyclodextrin (HPbetaCD) and then incorporated CAR/HPbetaCD binary systems in sustained-release tablets made of poly(ethyleneoxide) (PEO). Solid CAR/HPbetaCD binary systems were prepared by physical mixing, kneading, co-melting and freeze-drying methods and characterized by DSC and X-ray powder diffractometry. The amount of CAR dissolved from all the HPbetaCD-containing systems was higher than pure CAR, the co-molten and freeze-dried products showing the best dissolution performance. The incorporation of the binary systems in PEO tablets resulted in a CAR release rate much higher than tablets containing only CAR. It was found that the time necessary to achieve complete release from the tablet was linearly related to the dissolution parameters of CAR/HPbetaCD powders. In the case of co-molten and freeze-dried products, all CAR content could be released in about 12 and 10 h, respectively. Our results demonstrate that the incorporation of drug/cyclodextrin solid systems in erodable PEO matrices intended for the delivery of poorly water-soluble drugs is useful to modulate the release rate by controlling the dissolution properties of the drug inside the tablet.
Miro
Agnese
A
Dipartimento di Chimica Farmaceutica e Tossicologica, Università degli Studi di Napoli Federico II, 80131 Napoli, Italy.
Quaglia
Fabiana
F
Giannini
Lucia
L
Cappello
Brunella
B
La Rotonda
Maria Immacolata
MI
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000737:chemistry; D002227:Carbazoles / Q000008:administration & dosage / Q000737:chemistry; D000077261:Carvedilol; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D015195:Drug Design; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry; D011412:Propanolamines / Q000008:administration & dosage / Q000737:chemistry; D012995:Solubility; D014961:X-Ray Diffraction; D047392:beta-Cyclodextrins / Q000737:chemistry*
D000959:Antihypertensive Agents; D002227:Carbazoles; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004364:Pharmaceutical Preparations; D011412:Propanolamines; D047392:beta-Cyclodextrins; D000077261:Carvedilol; D000073738:2-Hydroxypropyl-beta-cyclodextrin